Recruiting

Longitudinal Study of Gene Expression in the Human Placenta During First-trimester and Full-term Pregnancy at the Single Cell Level

The single nucleus RNA-seq approach allows the placental transcriptome to be analyzed from nuclei, thus preserving the integrity of placental syncytium. This approach is feasible on small fragments of villi and offers for the first time the possibility to consider the characterization of gene expression within the structural unit of the human placenta during pregnancy (at the 1st trimester and childbirth)

ClinicalTrials.gov IDNCT06427408

PhaseNot Applicable

Enrollment100

SponsorAssistance Publique - Hôpitaux de Paris

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Pregnancy Related

About this study

Interventions

Other: Non applicable — Placental transcriptomic analysis

Primary outcomes

Analysis of the cellular transcriptomic trajectory of the human placenta (Day 0)
Analysis of the cellular transcriptomic trajectory of the human placenta (At childbirth)

Eligibility information

Inclusion Criteria: * Age 18 to 50 * Progressive monofoetal pregnancy between 11 and 15 weeks of amenorrhea * Patient with prenatal medical indication and requesting chorionic villus biopsy with cytogenetic analysis or molecular genetics * Patient scheduled for delivery at Port-Royal Maternity Hospital Exclusion Criteria: * Minor patient * Multiple pregnancy * Patient's objection * Without health insurance * Patient under guardianship or curatorship

Study locations

Maternité Port-Royal, Cochin hospital, Paris, IDF 75014 France

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.